| Autor: |
Chiara Sartor, Mario Arpinati, Gabriella Chirumbolo, Luca Dozza, Gianluca Cristiano, Jacopo Nanni, Giovanni Marconi, Valentina Robustelli, Ilaria Vigliotta, Sarah Parisi, Carolina Terragna, Nicoletta Testoni, Stefania Paolini, Giovanni Martinelli, Antonio Curti, Michele Cavo, Cristina Papayannidis |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Hematological oncologyREFERENCES. 40(4) |
| ISSN: |
1099-1069 |
| Popis: |
Antigen-directed target therapy for B-cell acute lymphoblastic leukemia (B-ALL) is now the standard of care for relapsed/refractory (R/R) disease. A comprehensive determination of the target itself is mandatory to aid physician's choice. We determined baseline Cluster of differentiation 22 (CD22) expression percentage and fluorescent intensity on lymphoblasts of 30 patients with R/R B-ALL treated with anti-CD22 immunoconjugate drug Inotuzumab Ozogamicin (INO) and analyzed the impact of both parameters on patient outcome. Most patients (24/30, 80%) had a high leukemic blast CD22-positivity defined as ≥90%. We did not observe a benefit in terms of complete remission, overall survival (OS) and duration of response (DoR) for patients with CD22 ≥ 90% versus CD22 90%. Concerning CD22-FI quartile analysis we appreciated a trend for superior response rates in higher quartiles (Q |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text